Recce Pharmaceuticals Limited (ASX: RCE) has completed tests involving a four-person cohort for its RECCE 327 (R237) synthetic antibiotic, which will be used to treat urinary tract infection (UTI) and urosepsis.
The four subjects were dosed by fast infusion, receiving 3,000 milligrams (mg) of R237 over 20 minutes.
The cohort testing was part of a wider program for Recce’s Phase I/II UTI/Urosepsis clinical trial, evaluating the drug at fast infusion rates, and work is now set to begin on data evaluation and review – to be undertaken by an Independent Safety Committee – and recruitment for the next testing cohort.
After that, Recce will progress to a Phase II UTI/Urosepsis efficacy trial for the drug, hoping to establish it as a frontline treatment for these conditions.
CEO James Graham said the results moved Recce one step close to achieving this goal.
“Completing dosing for our latest cohort marks another milestone in our journey advancing R327 as a potential frontline treatment for UTI/Urosepsis,” he said.
“We are dedicated to delivering impactful solutions to combat infectious diseases and improve global health outcomes globally.”
The value of R237 derives from the fact that administration of antibiotics through rapid intravenous infusions has been shown to impact patient treatment, wait times, and nursing workloads globally.
Recce Pharmaceuticals is trading at 44c.